Results from the THRIVE study found that when reading glasses were given to first-time wearers, monthly median incomes increased by 33%.

Trial findings show efficacy of lotilaner for killing mites

Catch up on what happened in optometry during the week of April 8-April 12.

Pterygium is an ocular disease commonly referred to as “surfer’s eye,” which can result from exposure to high levels of UV radiation.

Before the ASCRS 2024 meeting, TheiaNova CEO Carissa Fonseca, PhD, pitched a novel keratoconus treatment.

The Phase 1/2 study includes a dose-escalation phase of the study featuring 3 cohorts each one receiving either a low, medium, or high dose of OCU410.

The optometry school, founded in 1904, was the first of its kind in California.

The company selected LNZ100, designed to treat presbyopia, as its lead candidate and expects to submit an NDA in mid-2024.

The company now offers 3 different digital marketing plans for independent optometric offices, and will have a strategist dedicated to individual accounts.

The Phase 3 study will have a sample size of 150 participants—one arm of 75 participants with the RHO gene mutation and the other arm with 75 participants that are gene agnostic.

Bryan Wilson, executive director of medical affairs at Genentech, details why Birmingham, Alabama was chosen as the community to study the effects of diabetic eye disease among African Americans in a new manuscript from the ADA and Genentech.

The study authors also noted that patients responding well to routine intense pulsed light sessions do not need to undergo additional sessions.

Catch up on what happened in optometry during the week of April 1-April 5.

The Hadassah Self-Visual Acuity Screener (HSVA) has high test–retest reliability, accuracy, and alignment with clinical-standard VA tests, according to a study conducted by its developers.

The manuscript, "Breaking Barriers: Partnerships to Improve Diabetic Eye Health in Alabama," highlights the burden of diabetic eye disease in Alabama, as well as strategies that target racial health disparities within that population.

The trials will include patients with ocular hypertension, and assess QLS-111 in its efficacy for lowering IOP beyond levels currently achievable by targeting EVP.